2023-505079-65-00CompletedPhase 1
A Phase 1, Dose Finding Study of CC-92328 in Subjects with Relapsed and/or Refractory Multiple Myeloma.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 2 Jul 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 2 (actual)
- First submitted
- 30 Jun 2023
- Start date
- 1 Apr 2022
- Lead sponsor
- Celgene Corp.
- Diseases
- Multiple myeloma
- EU CT number
- 2023-505079-65-00
- EudraCT number
- 2020-005968-64
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 2
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (4)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Catala d'Oncologia | Badalona | Spain | Completed |
| Clínica Universidad de navarra | Pamplona | Spain | Completed |
| Hospital Universitario De Salamanca | Salamanca | Spain | Completed |
| Hospital Universitario Marqués de Valdecilla | Santander | Spain | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.